Table 5.
Treatment with dupilumab in patients with ABPA and asthma.
| Pre-treatment clinical variables | Post-treatment clinical variables | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study ID | Type of study | Sample | Gender | Age | Previous biologic treatment | Absolute eosinophil count (cell/µL) | Total IgE (IU/mL) | FEV1 (%predicted or L) | Frequency of acute exacerbations or asthma control test | Antifungal treatment | Follow-up time | Total eosinophil count (cell/µL) | Total IgE (IU/mL) | FEV1 (%predicted) | Frequency of acute exacerbations or asthma control test | Systemic steroids | Antifungal treatment | Adverse effects |
| Ramonell et al.30 | Case series | 3 | F | 60 | Omalizumab and Mepolizumab | 1620 | 561 | 1.51 L (58%) | NI | NI | 6 months | 1090 (4 mo) | 380 (3 mo) | 2.18 L (99%) | Improved | Discontinued | NI | hypereosinophilia |
| F | 51 | Mepolizumab | 1040 | > 2000 | 2.75 L (95%) | NI | Itraconazole | 3 months | 160 | 384 | 2.82 L (97%) | Improved | Discontinued | NI | No | |||
| M | 33 | No | 1750 | 11.290 | 1.97 L (37%) | NI | Voriconazole | 3 months | 690 | 1637 | 2.33 L (56%) | Asthma exacerbation after onset dupilumab | NI | NI | Hypereosinophilia | |||
| Corren et al.31 | Post Hoc analysis of an RCTf (35) | 18 | NI | NI | NI | NI | 3383 (1480–5000b | 2.00 L (68%)a | 2.28 (1.53)a,d | NI | 13 months | NI | 691,5 (323–2617)b | 24 w 2.26 52 w 2.33c | Improved | NI | NI | Injection-site reaction |
a
Mean (SD/range).
b
Median (range).
c
Mean (95% CI).
d
Frequency of acute exacerbations.
e
Asthma control test.
f
Liberty Asthma Quest study.
ABPA, allergic bronchopulmonary aspergillosis.